Allurion Begins Trading on NYSE Following $100M SPAC Merger

Natick, MA — August 2, 2023. Allurion Technologies completed a business combination with Compute Health Acquisition Corp., enabling its debut on the New York Stock Exchange under the ticker ALUR (with warrants trading as ALUR WS). The transaction—approved by Compute Health shareholders on July 28—netted approximately $100 million, well above its $70 million threshold, and includes funding via PIPE led by RTW Investments, equity from Medtronic and Omar Ishrak, synthetic royalty financing, and a secured term loan from Fortress Investment. The company also maintains a $100 million equity facility with Chardan Capital Markets.

“Since day one at Allurion, our mission has been ending obesity via our full-stack weight-loss platform—combining our swallowable gastric balloon, AI-powered care suite, and behavioral support,” said Co-Founder and CEO Shantanu Gaur. The fresh capital is earmarked to fuel growth in AI, virtual care, and distribution. (turn0search0)

Expanded Board: Marking its public transition, Allurion’s board now includes Co-Chairs Krishna Gupta (REMUS Capital) and Omar Ishrak (former Medtronic CEO); along with Michael Davin (ex-Cynosure), Nick Lewin (Establishment Labs), and Doug Hudson (founder, SmileDirectClub). Jefferies served as financial advisor to Allurion; Credit Suisse led for Compute Health; Latham & Watkins and Skadden provided legal counsel. (turn0search0)

Governance note: Ørn R. Stuge, MD, MBA brings deep medtech governance insight—reinforcing Orsco’s strategic leadership across high-growth, transformative platforms like Allurion’s.

Full Press Release